2021 marked a successful year for the protein degradation field with several candidates entering the clinic. As the European centric targeted protein degradation landscape matures and the number of pre-clinical candidates expected to enter clinical development in the next year grows ever more, the 2nd TPD Europe Summit returns, in person, to highlight key challenges and opportunities ahead!

Built with biopharma in mind, join us as we take a deep dive into how European leaders of protein degradation are approaching key translational challenges including optimisation of selectivity, bioavailability and PKPD to ensure the safety, efficacy and potency of their clinical pipelines in 2022 and beyond!

Be at the heart of the discussion by joining 180+ Senior Scientists, Principal Investigators & Heads of Discovery, Pre-Clinical & Translational Development from Europe and around the globe for two dedicated streams of exciting content over three days to capitalise on this emerging therapeutic class.

Key Highlights Not to Miss:

• Hear from Kevin Moreau, Assoicate Director PROTAC Safety Science, AstraZeneca as he discusses key PROTAC safety considerations for both oncology and non-oncology indications including how to optimise the safety profile, and what is acceptable for non-oncology targets

• Delve into COFFEE (covalent functionalisation followed by E3 electroporation), which tests neo-substrate degradation by chemically modified E3 ligase components. Brought to you by Benika Pinch, Principal Scientist, Novartis, she discusses how to assess the cellular activity of E3 ligase components

• Uncover how protein manipulation using peptides can be used to degrade proteins using either the UPS or lysosomal pathways. This exciting approach relocates protein within the cell and modulates their interactions. Hear Max Cynader, CEO & Co-Founder Primary Peptides discuss in detail!

• Amine Sadok, Head of Biology at Monte Rosa Therapeutics will be discussing how they have identified a potent and selective NEK7 molecular glue degrader as a novel CRBN neo-substrate

Digital passes available

To know more visit: https://ter.li/j3ytqu